Browsing Tag
gemcitabine
6 posts
Could repeated VCN-01 dosing overcome long-standing survival barriers in metastatic PDAC?
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Discover what this means for trial execution and survival outcomes.
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
Johnson & Johnson fortifies urologic oncology pipeline with compelling Inlexzo results
Johnson & Johnson's new data show Inlexzo delivers strong one-year disease-free survival. Find out how it could shift bladder cancer care.
Relmada gains FDA support for dual Phase 3 study paths of NDV-01 in non-muscle invasive bladder cancer
Find out how Relmada secured FDA alignment on dual Phase 3 paths for NDV-01 in NMIBC, opening two routes toward approval and a potential new bladder-sparing therapy.
Understanding pancreatic cancer: causes, symptoms, tests, and treatments explained
Learn everything about pancreatic cancer in this comprehensive guide—what causes it, how it develops, signs to watch for, diagnostic methods, and current treatment options.
Zentalis Pharmaceuticals reports promising results from Phase 1 trial of azenosertib, gemcitabine combo
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a trailblazer in developing small molecule therapeutics for cancer, has released the final…